The Number of FDA-Approved Autologous CAR T Cell Therapies Continues to Grow!

Bristol Myers Squibb’s Breyanzi Receives FDA Approval. Breyanzi is Cryopreserved in CryoStor® CS10.  On Friday, February 5th, 2021, the U.S. Food and Drug Administration published a press release announcing the approval of CD19-targeting CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi is approved to treat adult patients with relapsed or refractory large B-cell lymphoma…

Read More

Journal Articles Citing CryoStor CS10® Recently Added to BioLife Solutions’ Evidence Library

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…

Read More

Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library

Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient…

Read More